Western Washington University

Western CEDAR
WWU Honors College Senior Projects

WWU Graduate and Undergraduate Scholarship

Spring 2021

Structure of Blood Coagulation Factor VIII in Complex with AntiC2 Domain Inhibitory Antibody
Estelle K. Ronayne
Western Washington University

Shaun C. Peters
Western Washington University

Joseph Gish
Western Washington University

Celena Wilson
Western Washington University

H. Trent Spencer
Emory University

See next page for additional authors
Follow this and additional works at: https://cedar.wwu.edu/wwu_honors
Part of the Art and Design Commons, Biochemistry, Biophysics, and Structural Biology Commons, and
the Chemistry Commons

Recommended Citation
Ronayne, Estelle K.; Peters, Shaun C.; Gish, Joseph; Wilson, Celena; Spencer, H. Trent; Doering, Christopher
B.; Lollar, Pete; Spiegel, P. Clint Jr.; and Childers, Kenneth C., "Structure of Blood Coagulation Factor VIII in
Complex with Anti-C2 Domain Inhibitory Antibody" (2021). WWU Honors College Senior Projects. 487.
https://cedar.wwu.edu/wwu_honors/487

This Project is brought to you for free and open access by the WWU Graduate and Undergraduate Scholarship at
Western CEDAR. It has been accepted for inclusion in WWU Honors College Senior Projects by an authorized
administrator of Western CEDAR. For more information, please contact westerncedar@wwu.edu.

Authors
Estelle K. Ronayne, Shaun C. Peters, Joseph Gish, Celena Wilson, H. Trent Spencer, Christopher B.
Doering, Pete Lollar, P. Clint Spiegel Jr., and Kenneth C. Childers

This project is available at Western CEDAR: https://cedar.wwu.edu/wwu_honors/487

Structure of Blood Coagulation Factor VIII in Complex with Anti-C2 Domain
Inhibitory Antibody
Estelle K. Ronayne1, Shaun C. Peters1, Joseph Gish1, Celena Wilson1, H. Trent Spencer2, Christopher B.
Doering2, Pete Lollar2, P. Clint Spiegel, Jr.1, Kenneth C. Childers1.
1

Department of Chemistry, Western Washington University, Bellingham, WA, USA

2

Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta,
Emory University, Atlanta, GA, USA
Abstract
Factor VIII (fVIII) is a procoagulant protein that binds to activated factor IX (fIXa) on platelet surfaces to
form the intrinsic tenase complex. Due to the high immunogenicity of fVIII, generation of antibody
inhibitors is a common occurrence in patients during hemophilia A treatment and spontaneously occurs
in acquired hemophilia A patients. Non-classical antibody inhibitors, which block fVIII activation by
thrombin and formation of the tenase complex, are the most common anti-C2 domain pathogenic
inhibitors in hemophilia A murine models and have been identified in patient plasmas. In this study, we
report on the X-ray crystal structure of a B domain-deleted bioengineered fVIII bound to the non-classical
antibody inhibitor, G99. While binding to G99 does not disrupt the overall domain architecture of fVIII,
the C2 domain undergoes an ~8 Å translocation that is concomitant with breaking multiple domaindomain interactions. Analysis of normalized B-factor values revealed several solvent-exposed loops in
the C1 and C2 domains which experience a decrease in thermal motion in the presence of inhibitory
antibodies. Our results enhance our understanding on the structural nature of binding non-classical
inhibitors and provide a structural dynamics-based rationale for cooperativity between anti-C domain
inhibitors.
Introduction
Hemophilia A is an X-linked recessive disorder caused by mutation to the F8 gene which results in a
deficiency of coagulation factor VIII (fVIII), where severe mutations abolish fVIII production completely.
Patients with hemophilia A are prone to uncontrolled bleeding events and require regular infusions of
recombinant or plasma-derived fVIII to maintain functional coagulation (1,2). In approximately 30% of
hemophilia A treatment cases, patients will produce antibodies that inhibit infused fVIII and reduce
treatment efficacy (3,4). Furthermore, acquired hemophilia A can develop in healthy individuals through
an autoimmune response, producing antibody inhibitors which bind to and inhibit the cofactor activity
of native fVIII (5). Immune tolerance induction has been demonstrated to overwhelm the immune
system through frequent, high-dosages of fVIII with modest success (3), but can be a physical and
financial burden for the patient (6).
Coagulation fVIII is a multidomain glycoprotein that circulates in the bloodstream as a heterodimer of
the heavy chain (A1-A2) and light chain (A3-C1-C2) while bound to von Willebrand factor (vWf) to

prevent premature clearance and/or degradation (2,7). Once cleaved by thrombin, activated fVIII (fVIIIa)
dissociates from vWf and binds activated platelet surfaces, likely through embedding several solventexposed hydrophobic loops on the C1 and C2 domains (8–10). Binding to activated factor IX (fIXa), a
serine protease, forms the ‘intrinsic’ tenase complex which amplifies the generation of activated factor
X (fXa) and subsequently thrombin.
One example of a fVIII replacement therapeutic is ET3i, a bioengineered human-porcine chimera of Bdomain deleted fVIII. ET3i consists of porcine A1 and A3 domains and human A2, C1, and C2 domains.
Domain swapping was employed to increase protein expression and stability, while still maintaining
function (11,12). Additionally, ET3i undergoes slower A2 dissociation upon activation by thrombin,
prolonging half-life (13).
Previous studies indicate the A2, C1, and C2 domains to be highly immunogenic, where C2 is
immunodominant (4,14–17). Anti-C2 domain inhibitors represent a diverse group of fVIII neutralizing
antibodies and are categorized as classical and non-classical antibodies (18–20). Classical antibodies
inhibit fVIII binding to vWf and platelet surfaces and their associated epitopes are categorized into
groups A, AB or B (18). X-ray crystal structures of the isolated C2 domain bound classical inhibitors such
as BO2C11 (21) and 3E6 (22,23) have identified unique conformational epitopes and demonstrated how
inhibitor binding reduces circulatory levels of fVIII. Conversely, non-classical antibodies prevent fVIII
activation by thrombin or fXa and their epitopes are categorized into groups BC and C (18). Non-classical
antibodies are the most common pathogenic inhibitors in hemophilia A murine models (18) and
inhibitors with overlapping epitopes have been detected in hemophilia A patient plasma (19). Group BC
inhibitors are the most common anti-C2 antibodies and display above-average titer levels, particularly
in patients with acquired hemophilia A (18), representing a significant clinical complication. In the
presence of non-classical inhibitors, the binding of classical inhibitors to fVIII has been shown to increase
(24). Additionally, hydrogen-deuterium exchange (HDX) protection patterns suggest cooperativity
between anti-fVIII inhibitors, G99 and 3E6 (25).
The pathogenic, non-classical antibody inhibitor G99 is a group BC inhibitor and binds to several solventexposed loops in the C2 domain that are predicted to interact with thrombin and fIXa (26,27).. Epitope
mapping based on HDX rates indicate residues 2200-2228 are a major determinant in G99 binding (28),
including K2227 which, upon substitution with glutamic acid, abrogates fVIII binding to G99 (18). The
crystal structure of the isolated C2 domain bound to G99 identified a conformational epitope composed
of multiple loops and revealed K2227 forms multiple electrostatic contacts with the G99 light chain (22).
Here, we present the crystal structure of ET3i (29–31) bound to the G99 antigen binding fragment (FAB).
Our structure represents the first crystal structure of a fVIII replacement therapeutic bound to an antiC2 inhibitor, providing insight into how non-classical inhibitors alter the C2 domain conformation of
mature fVIII and allosterically influence the thermal motion of nearby epitopes.
Materials and Methods
Expression and Purification of ET3i
ET3i was expressed and purified as previously described (29,30) to a final concentration of 0.8 mg/mL
and stored in 50 mM HEPES, pH 7.4, 5 mM CaCl2 and 350 mM NaCl at -80 °C.

Purification of G99 FAB Fragments
G99 monoclonal antibodies were expressed and purified in hybridoma cell lines and FAB fragments were
prepared as previously described (18,22). Briefly, large-scale antibody production was performed at the
Antibody Production Facility at the Fred Hutch (Seattle, WA). Immunoglobulin (IgG) and FAB purifications
were completed with Protein A Plus spin columns and immobilized papain kits (Thermo Scientific,
Rockford, IL) according to the manufacturer’s protocols. Purified FAB fragments were stored at a final
concentration of 10 mg/mL at -80 °C in FAB storage buffer (25 mM Tris-HCl pH 7.2, 100 mM NaCl).
Crystallization, Data Collection, and Refinement
The ET3i:G99 FAB complex was formed at a 1:1.2 stoichiometric ratio in 50 mM Tris HCl (pH 7.4), 200 mM
NaCl, and 2.5 mM CaCl2 and purified using a 100 kDa MWCO spin column (Amicon) to 1 mg/mL. Initial
crystal conditions were determined via high-throughput microbatch crystallization using the HauptmanWoodward High-Throughput Crystallization Center (Buffalo, NY) (27). Diffraction quality crystals were
subsequently grown by hanging drop vapor diffusion in a 1:1 (v/v) ratio of the ET3i:G99 protein complex
and crystallization solution containing 50 mM malic acid (pH 7.0) and 8-18% (w/v) PEG 1500, PEG 6000,
or PEG 10,000. Crystals were cryoprotected in mother liquor with the stepwise addition of 30% (v/v)
glycerol. X-ray diffraction data were collected on the Advanced Light Source (ALS) Berkeley Center for
Structural Biology (BCSB) beamline 5.0.1 (Berkeley, CA). Data collection and processing were performed
with Adxv, XDS and CCP4 (32).. Phasing of the ET3i:G99 crystals was determined with PHASER-MR using
a fragment-based molecular replacement approach with the previously determined 3.2 Å structure of
ET3i (PDB ID: 6MF0) and the 2.47 Å structure of human factor VIII C2 domain in complex with murine
inhibitory antibodies 3E6 and G99 (PDB ID: 4KI5) (22,31,33). Model building and refinement were
performed with WinCoot and PHENIX, respectively (34). All figures were generated with the PyMOL
Molecular Graphics System, Version 2.0 (Schrödinger, LLC).
Results
Crystal Structure of Factor VIII in Complex with the Anti-C2 Domain G99 Antibody
The X-ray crystal structure of the ET3i B domain-deleted fVIII construct bound to G99 was determined at
4.15 Å resolution and refined to Rwork/Rfree values of 0.2998/0.3384 (PDB ID: 7KBT) (Figure 1A, Table S1).
The asymmetric unit (ASU) contains one molecule consisting of the A1, A2, A3, C1, and C2 domains of
ET3i and the variable domains of the heavy and light chains of G99. While the FAB constant domains were
included in the protein complex, these domains could not be modeled into the final structure,
presumably due to flexibility, and thus were excluded. The ET3i:G99 complex superimposes well with
the crystal structure of the isolated C2 domain bound to G99 (PDB ID: 4KI5) (22) with a root-mean-square
deviation (RMSD) value of 0.81 Å2 (Figure 1B). Both complexes have structurally identical epitopes for
the G99 inhibitor antibody which encompass residues 2193-2194, 2222-2229, 2161-2163, 2269-2282,
and 2307-2311 (Figure 1C). The nature of the C2/G99 binding interface relies on a combination of polar
and hydrophobic interactions. Figure 1D illustrates how K2227 is a critical residue for binding to G99,
participating in multiple electrostatic interactions with E50, T99, and Y96. The epitope spanning residues
2222-2229 provides multiple points of contact with the heavy chain of G99 (Figure 1E), including E2228
which has been proposed to interact with the Gla domain of fIXa (27). Lastly, residues L2261, L2273,

V2280, and V2282, previously suggested as a binding site for thrombin (26), form direct, extensive
contacts with the G99 light chain (Figure 1F). Our structure of ET3i bound to the G99 FAB fragment
illustrates how non-classical inhibitors potentially block the binding of thrombin, fXa and fIXa, thus
preventing dissociation from vWf and formation of the tenase complex.

Figure 1. Crystal structure of ET3i bound to the G99 FAB fragment. (A) Cartoon representation of the B domain deleted
bioengineered fVIII construct (ET3i) bound to the variable domain of G99 inhibitor antibody. Porcine A1 and A3 (pA1 and
pA3) domains are colored dark red and pink, respectively, and human A2, C1, and C2 (hA2, hC1, and hC2) domains are
colored cyan. Heavy and light chains of the G99 FAB fragment (G99HC and G99LC) are colored green and purple, respectively.
N-acetylglucosamine modifications are depicted as sticks. (B) Ribbon diagram of aligned C2 domain (cyan) and G99 heavy
and light chains (green and purple, respectively) from the ET3i:G99 crystal structure and of the isolated C2 domain bound
to G99 (grey; PDB ID: 4KI5) in stereo view. (C) Stick representation of the G99 epitope from the ET3i:G99 (cyan) and C2:G99
(grey, faded) crystal structures. (D,E) Electrostatic contacts between ET3i epitope 2222-2229 (cyan) and G99 heavy chain
(green) and light chain (purple). Dotted lines depict hydrogen bonds (distance ≤ 5 Å). (F) Hydrophobic residues along the
ET3i epitope 2269-2282 (cyan) buried by the G99 light chain (purple).

Binding G99 Induces a Conformational Rearrangement to the C2 Domain in Mature Factor VIII
Alignment of the ET3i:G99 complex to the unbound ET3i structure (PDB ID: 6MF0) (31) suggests that
binding G99 does not disrupt the overall ET3i structure, with an average RMSD of 0.68 Å2 (Figure 2A).

The C2 domain, however, shows the largest
conformational change upon binding G99 (Figures
2B, 2C), undergoing an ~8 Å translocation relative
to the other ET3i domains. Most of these
conformational changes are localized to several
loops proximal to the G99 epitope, including
residues 2256-2265, 2270-2285, and 2305-2314.
This rearrangement to the C2 domain is
concomitant with breaking multiple interfacial
contacts with the adjacent A1 and C1 domains
(Figure 2A). The A1/C2 interface includes
interactions between amino acids E123, N2172,
and K2239 that are disrupted due to K2239
shifting by 5 Å in the ET3i:G99 structure. The
C1/C2 interface includes interactions between
amino acids H2031 and S2296, and D2170 and
S2175, both of which become disrupted in the
ET3i:G99 complex. Lastly, the ET3i:G99 crystal
structure reveals loss of an intramolecular contact
within the C2 domain between R2304 and Q2266.
While the extent of disruption to these
interactions is not definitive given the lower
resolution of the crystallographic data, the
structure of ET3i:G99 does show significant
rearrangement to the C2 domain with the greatest
conformational changes occurring to the
aforementioned regions.
Analysis of B-Factor Values from Multiple ET3i
Crystal Structures
To further investigate how inhibitor binding
influences the flexibility of C domain epitopes, we
performed a comparative B-factor analysis on the
C1 and C2 domains from several crystal structures
of ET3i bound to antibody inhibitors as well as the
unbound ET3i structure (Figures 3A, 3B). B-factor
values are calculated by the spatial fluctuation of
atoms in a crystal structure from their equilibrium
positions (35) and provide insight into protein
structure thermostability, with low values indicating rigidity and high values indicating flexibility (units,
Å2). In addition to the unbound ET3i and ET3i:G99 crystal structures, we also included the crystal
structure of ET3i complexed with the anti-C1 domain inhibitor 2A9 (PDB ID: 7K66) in our analysis as the
C2 domain in this structure undergoes a similar translocation (36). To better compare between each
Figure 2. Structural alignment of unbound ET3i and
ET3i:G99 crystal structures. (A) Alignment of unbound ET3i
(grey) and ET3i:G99 (A1: dark red, A3: pink, A2/C1/C2: cyan).
Insets depict intramolecular contacts that are broken in the
ET3i:G99 structure. (B) Alignment of the C2 domain from
unbound ET3i structure (grey) and ET3i:G99 structure (cyan).
(C) Structure of the C2 domain from the ET3i:G99 complex
colored as a function of RMSD from alignment with unbound
ET3i. White: low RMSD shifts, orange: large RMSD shifts.

crystal dataset and reduce bias in this study, normalized B-factor values (B’) were calculated using the
following equation:
𝑩
𝑩′ = "𝑩
(1)
#(𝐑𝐞𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧)
𝒂𝒗𝒆𝒓𝒂𝒈𝒆

where B is the raw atomic B-factor, Baverage is the average B-factor of the ET3i molecule in the crystal
asymmetric unit, and Resolution is the reported atomic resolution for the respective structure. Model A
of the unbound ET3i crystal structure, which has two ET3i molecules in the ASU (31), was used to
compare with the antibody-bound structures.
The average B’ values at known C1 and C2
domain epitopes (Figure 3C) from three
ET3i crystal structures were tabulated for
comparison (Table 1). As expected, regions
that experience some of the greatest
decreases in B’ values occur directly at the
epitopes from the antibody-bound
structures. Residues 2065-2070, 21102112, and 2150-2156 in the ET3i:2A9
structure, which encompass the 2A9
epitope, have 35.2%, 27.2%, and 26.1%
lower B’ values, respectively, compared to
the free ET3i structure (Figure S1). Similarly,
residues 2269-2282, which form extensive
interactions with the G99 antibody, have a
37.9% lower average B’ value in the
ET3i:G99 complex than the unbound ET3i
structure (Figure S2). These observed
differences in B’ values are due to the
inhibitory antibody binding to the
respective epitope and reducing atomic
motions.

Figure 3. Anti-C domain inhibitors reduce atomic B-factors on
solvent-exposed loops. (A,B) Normalized atomic B-factors averaged
for each epitope in the (A) C1 domain and (B) C2 domain from
unbound ET3i (black, PDB ID: 6MF0), ET3i:G99 (blue, PDB ID: 7KBT),
and ET3i:2A9 (red, PDB ID: 7K66). (C) Cartoon representation of the
C1 and C2 domains from the unbound ET3i crystal structure (PDB ID:
6MF0, model A). Antibody epitopes are highlighted (2A9: magenta,
G99: green, 3E6: cyan, BO2C11: orange).

Previous work focusing on the atomic Bfactors from crystal structures of the
isolated C2 domain bound to classical and
non-classical
inhibitory
antibodies
identified fluctuations to the thermostability
in certain epitopes (17,23). We sought to
expand our understanding on this topic by
calculating the B’ values in the C1 and C2
domain epitopes when the opposing
domain was bound to an inhibitory
antibody. Our results indicate that antibody
binding is a potent allosteric modulator of

atomic motions to adjacent epitope (Table 1). For instance, residues 2269-2282, which participate in
binding G99 to the C2 domain, have a 24.4% lower average B’ value in the ET3i:2A9 structure than the
unbound ET3i structure. Similarly, B’ values from residues that comprise the 2A9 epitope in the ET3i:G99
crystal structure are lower than the unbound ET3i structure, most notably residues 2065-2070 which
have a 23.5% lower average B’ value. By calculating the average B’ value for each amino acid at these
epitopes, we determined that P2067 and F2068 of residues 2065-2070 and Q2276, N2277, and G2278
of residues 2069-2282 experience the greatest reduction in atomic motions (Figures S1 and S2). None of
the aforementioned “coldspots” participate in lattice contacts within the protein crystal, indicating an
alternate mechanism for reducing peptide flexibility. While differences in B’ values can be due to
variables that are unaccounted for in equation 1, such as crystallization conditions or refinement
strategy, these results are indicative of an allosteric relationship between anti-C1 and anti-C2 epitopes
in the presence of inhibitor antibodies.
Table 1. Average B’ values for C1 and C2 domain epitopes. Values in parentheses depict percent differences from
the unbound ET3i structure. Bold values represent differences that are greater than the average ET3i molecule
(“coldspots”).
ET3i

ET3i:G99

ET3i:2A9

0.307

0.241 (-21.5%)

0.255 (-16.9%)

2065-2070

0.322

0.247 (-23.5%)

0.209 (-35.2%)

2110-2112

0.352

0.235 (-33.1%)

0.256 (-27.2%)

2150-2156

0.260

0.218 (-16.4%)

0.192 (-26.1%)

2193-2194

0.319

0.264 (-17.5%)

0.279 (-12.6%)

2222-2229

0.323

0.263 (-18.4%)

0.284 (-12.0%)

2261-2263

0.294

0.241 (-18.0%)

0.260 (-11.5%)

2269-2282

0.422

0.262 (-37.9%)

0.319 (-24.4%)

2307-2311

0.286

0.239 (-16.3%)

0.266 (-7.1%)

2181-2188

0.311

0.257 (-17.4%)

0.293 (-5.9%)

2202-2215

0.326

0.269 (-17.5%)

0.267 (-18.3%)

2195-2202

0.404

0.291 (-28.0%)

0.339 (-16.0%)

2247-2255

0.337

0.251 (-25.5%)

0.270 (-19.9%)

A1-A2/A3-C1-C2
2A9 epitope

G99 epitope

3E6 epitope

BO2C11 epitope

We next investigated the atomic thermostability for residues spanning the epitopes for 3E6 and BO2C11
antibodies, which bind to unique regions on the C2 domain (Figure 3C) and are categorized as classical
inhibitors (21–23), in the ET3i:G99 and ET3i:2A9 crystal structures. We measured reduced B’ values for
the 3E6 epitope in the ET3i:2A9 and ET3i:G99 structures when compared with the unbound ET3i
structure. Specifically, the 3E6 epitope spanning residues 2202-2215 had an 18% lower average B’ in

both inhibitor-bound crystal structures (Table 1, Figure S3). Residues 2195-2202 and 2247-2255, which
encompass the BO2C11 epitope (21), have 16% and 19.9% lower B’ values in the ET3i:2A9 crystal
structure, respectively, and are even lower in the ET3i:G99 structure (28.0% and 25.5%, respectively)
(Table 1, Figure S4). Taken together, these results support the hypothesis that these regions on the C2
domain become more rigid when bound to either G99 or 2A9.
Discussion
In this study, we report on the crystal structure of ET3i, a bioengineered fVIII molecule, bound to the
pathogenic, non-classical antibody inhibitor G99. While the A domains are structurally unperturbed by
G99 binding, the C2 domain undergoes an ~8 Å translocation and loses multiple intramolecular contacts
with the adjacent A1 and C1 domains. Mutations at the A1/C2 and C1/C2 domain interfaces have been
identified in multiple hemophilia A cases, including E123K, K2239E, and R2304L/G/C (37–40).
Considering the crystal structure of ET3i:G99 indicates binding to G99 disrupts these domain-domain
contacts, we speculate how mutations to these regions influence the C2 domain conformation and
inhibitor binding. In a previous surface plasmon resonance-based study with a suite of fVIII point
mutants, researchers mapped the epitopes of 11 anti-C2 antibody inhibitors and identified several
residues that are not part of a contiguous epitope, yet significantly impact binding to anti-C2 inhibitors
when mutated (41). K2239, which participates in multiple hydrogen bonds at the A1/C2 domain interface
(Figure 2A), demonstrated slightly stronger binding with the classical antibody 3E6 when substituted
with alanine. Furthermore, R2304C, which is linked to moderate cases of hemophilia A and high inhibitor
titer levels (38,40), has been proposed to destabilize fVIII without disrupting vWf and phospholipid
binding (42). These data are indicative of a unique relationship between C2 domain-domain contacts and
fVIII immunogenicity. Disruption to domain interfacial contacts may induce a structural rearrangement
to the C2 domain and enhance immune recognition and inhibitor binding. Our structure of the ET3i:G99
complex provides evidence for a connection between disruption to domain-domain contacts near the
C2 domain and inhibitor binding.
Normalization and comparison of B-factors between different crystal structures has previously been
utilized to study the effects of ligand binding (43), mutagenesis (44), environmental pH (45), as well as
protein engineering to enhance stability (46). Our analysis of normalized B-factors from several ET3i
structures in the absence and presence of inhibitor antibodies suggests that binding G99 induces
structural rigidity in multiple solvent-exposed regions of the C domains that are not a part of the G99
epitope. HDX protection patterns have been identified for residues 2231-2252 using the isolated C2
domain bound to G99 (28). Our results support these findings, with the greatest reduction in atomic
motions occurring to residues 2249-2252 at both the amino acid functional group and the peptide
backbone (Figure S2).
Adjustments to the thermostability in certain fVIII epitopes raise important questions regarding immune
recognition and cooperativity between classical and non-classical anti-C2 domain inhibitors. Indeed,
synthetic peptides encompassing the G99 epitope have been shown to stimulate CD4+ T-cell
proliferation and induce an immune response, including residues 2301-2320 which had the strongest
response among acquired hemophilia A patients (17). Because the degree of peptide flexibility is a strong
determinant in T-cell recognition and binding to T-cell receptors (47–49), reducing the dynamic mobility

in certain fVIII epitopes is a potential mechanism in fVIII immune recognition. Furthermore, group A
classical inhibitors have elevated association rates with fVIII when in the presence of non-classical group
BC antibodies (24,50), providing evidence for a cooperative immune response to fVIII. HDX
measurements on the isolated C2 domain pre-mixed with G99 and 3E6 had stronger protection patterns
than the individually bound complexes (25). Structural characterization of the C2 domain bound to G99
and 3E6 FAB fragments supports a polyclonal response to fVIII (22,51). Our analysis of normalized Bfactors suggests that cooperativity between inhibitors relies on reducing local disorder to these regions.
Lowering atomic motions may reduce the conformational diversity of certain epitopes, thereby
decreasing the entropic cost in macromolecular association, to provide a high-affinity binding site for
antibody inhibitors (23,52,53). Modification of these epitopes to prevent rigidification and promote
conformational diversity may present a novel strategy in the design of fVIII replacement therapeutics
with reduced immunogenicity.
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Supplementary Material
Table S1. X-ray data collection and refinement statistics.
Wavelength (Å)
Resolution range (Å)
Space group
Unit cell
Total reflections
Unique reflections
Multiplicity
Completeness (%)
Mean I/sigma(I)
Wilson B-factor
Rmerge
Rmeas
Rpim
CC1/2
CC*
Reflections used in refinement
Reflections used for Rfree
Rwork
Rfree
Number of non-hydrogen atoms
macromolecules
ligands
Protein residues
RMS (bonds)
RMS (angles)
Ramachandran favored (%)
Ramachandran allowed (%)
Ramachandran outliers (%)
Rotamer outliers (%)
Clashscore
Average B-factor
macromolecules
ligands

1
25.48 - 4.15 (4.298 - 4.15)
P 41 21 2
a = 132.243, b = 132.243, c = 380.029; α, β, γ = 90°
52,566 (50,92)
26,284 (2,546)
2.0 (2.0)
99.08 (98.31)
6.31 (0.48)
195.91
0.06373 (1.359)
0.09012 (1.922)
0.06373 (1.359)
0.998 (0.373)
1 (0.737)
26,198 (2,504)
1,987 (191)
0.2998 (0.4645)
0.3384 (0.4481)
11,366
11,293
73
1,444
0.005
1.07
78.02
15.15
6.83
0.08
15.7
253.38
253.25
273.82

Supplementary Figure 1. Atomic B’ values per amino acid for 2A9 epitope. (Left) Cartoon structure of the
C1 domain highlighting 2A9 epitope (magenta). (Right) Solid circles represent the average B’ of the amino
acids and faded circles represent the B’ value of the Cα atoms from unbound ET3i (black, PDB ID: 6MF0),
ET3i:G99 (blue, PDB ID: 7KBT), and ET3i:2A9 (red, PDB ID: 7K66).

Supplementary Figure 2. Atomic B’ values per amino acid for G99 epitope. (Left) Cartoon structure of the
C2 domain highlighting G99 epitope (green). (Right) Solid circles represent the average B’ of the amino acids
and faded circles represent the B’ value of the Cα atoms from unbound ET3i (black, PDB ID: 6MF0), ET3i:G99
(blue, PDB ID: 7KBT), and ET3i:2A9 (red, PDB ID: 7K66).

Supplementary Figure 3. Atomic B’ values per amino acid for 3E6 epitope. (Left) Cartoon structure of the
C2 domain highlighting 3E6 epitope (cyan). (Right) Solid circles represent the average B’ of the amino acids
and faded circles represent the B’ value of the Cα atoms from unbound ET3i (black, PDB ID: 6MF0), ET3i:G99
(blue, PDB ID: 7KBT), and ET3i:2A9 (red, PDB ID: 7K66).

Supplementary Figure 4. Atomic B’ values per amino acid for BO2C11 epitope. (Left) Cartoon structure of
the C2 domain highlighting BO2C11 epitope (orange). (Right) Solid circles represent the average B’ of the
amino acids and faded circles represent the B’ value of the Cα atoms from unbound ET3i (black, PDB ID:
6MF0), ET3i:G99 (blue, PDB ID: 7KBT), and ET3i:2A9 (red, PDB ID: 7K66).

